Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

    For further information please contact:


    Porter Novelli for Shire


    Marion E. Glick

    212.601.8273

    917.301.4206 (on site at APA)


    Debra Gemme

    212.601.8342

    703.298.4030 (on site at APA)

All GXR Posters will be presented in Sails Pavilion, Upper Level in the San Diego Convention Center

APA Poster # NR659

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents with Attention- Deficit/Hyperactivity Disorder (Trial 301)

J. Biederman, M.D.; R. Melmed, M.D.; A. Patel, M.D.; K. McBurnett, M.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

APA Poster # NR656

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Randomized, Double-Blind Study of Guanfacine Extended Release in Children Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder (Trial 304)

F. Sallee, M.D.; J. McGouth; T. Wigal, Ph.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.; J. Biederman, M.D.

APA Poster # NR658

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Long-Term, Open-Label Study of Guanfacine Extended Release in Children and Adolesce
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/4/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... the agreement, Isis is eligible to receive up to ... million up-front payment and a $55 million payment upon ... in patients with compromised kidney function. Isis is also ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, today ... 28, 2015. Net sales for the first ... 1.4% compared with the first quarter of 2014.  This ... 6.0% decline related to foreign currency exchange.  In local ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17
... overall survival rate from,cancer now is lower in older ... in part because of a lack of access to ... a study by pediatric,oncologists at Children,s Hospital of Pittsburgh ... than 15 with cancer have,improved dramatically over the last ...
... Period -, EXTON, Pa., Jan. 15 ... been completed in the pivotal,Phase III multi-center, double-blind, ... the treatment of,nasolabial folds, or wrinkles (Studies IT-A-005 ... of the study., Isolagen also announced the ...
Cached Medicine Technology:Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 2Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 3Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies 2
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... New West Medicare is excited to ... to manage outpatient advanced imaging services for its members. ... its members are provided the right test at the ... with New West Medicare’s physicians and hospitals, Care to ... advanced imaging and provide an objective basis for informed ...
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living with ... others in similar situations that they were not alone, in ... Discovery of New Energy” (published by Balboa Press). This year ... renewed press campaign. , “I have spent nearly 60 years ... says. “As an adolescent I got into trouble with an ...
(Date:5/4/2015)... Fast on the heels of Autism Awareness ... Allison Folmar, JD, join over 150 speakers in the ... Sunday, May 24, the conference presents "I Know You're ... interested in Ryan Hinds' recovery story? The book ... autism was written by Marcia Hinds, Ryan’s mom. ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... chemically-modified version of a mitochondrial toxin long used to ... found to selectively inhibit two "survival proteins in ... step toward developing a molecularly-targeted drug that could eliminate ... therapy found in many types of cancers. ,scientists ...
... just how important it is for mothers-to-be to relax, by ... their offspring will develop cerebral palsy . ,Cerebral ... disability. ,Though the study was conducted on a ... sante et de la recherche medicale, the French public biomedical ...
... together to plug the site of injury in the form ... aggregation can block blood vessels and cause heart attack ... many molecules to platelet integrin alpha-IIb beta 3, and blockade ... clots. ,However, chronic use of oral drugs that ...
... for neuroblastoma that lands a one-two punch works best when ... of the first one, according to results of studies at ... tumor that arises from cells in the peripheral nervous system. ... by using the drug bevacizumab to block VEGF, a protein ...
... tobacco industrys deceptive practices have been aggressively quashed through ... Ibrahim , co-author of an analysis in the August ... ,In the article, Ibrahim tracks the rise and ... for the past 40 years. She chronicles industry strategies ...
... the long-standing claim that organic farming methods cannot produce ... can yield up to three times as much food ... on the same land. ,Researchers from the ... were almost equal on organic and conventional farms. ...
Cached Medicine News:Health News:Cell Toxin Inhibits Survival Protein in Cancer Cells 2Health News:Tumor Blood Flow can Improve Chemotherapy 2Health News:Tumor Blood Flow can Improve Chemotherapy 3Health News:Tobacco Industry Promotes Antismoking Campaigns 2Health News:Tobacco Industry Promotes Antismoking Campaigns 3Health News:Organic Farming can Feed the World, U-M Study Shows 2Health News:Organic Farming can Feed the World, U-M Study Shows 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: